Many studies have shown that chemotherapy-immunotherapy combinations achieved prolonged progression-free survival (PFS) and overall survival (OS) in advanced NSCLC patients regardless of the PD-L1 expression level and also improved survival than chemotherapy alone (3). Here, CD274 is linked to non-small cell lung carcinoma.